Class-I medical device — filed
Production and operation filings for the cell-preparation line are on record with the local administration. Certificate below.
Own inventions, published
The NuoqTFF™ 1.0 line and supporting devices are covered by our own patent family — including CN112877190A, a storage-transport umbilical cord blood filtration device, among high-value invention filings.
We draft the rules we ship under
Contributor to the national guideline on exosome particle-size and concentration measurement, and drafter of group standards covering EV nebulized-inhalation therapy, dental-pulp cell preparation and storage, and immune-cell isolation and storage.
Independent lab verification
Exosome product tested by Zhongke Ruiji (Jiaxing) — an independent third-party laboratory. Full virology panel negative (HBV-DNA, HIV-I/II RNA) plus complete quality characterization.
Invention patent granted
Patent No. ZL 2021 1 0013641.0 — "Umbilical cord blood filtration device for storage and transport" (Certificate No. 5230932). Patent holders include our own team members. Granted June 2022, valid 20 years.
Registered and compliant
Founded June 2021 with RMB 10 million registered capital. Business scope explicitly covers cell technology R&D and technical services.
